Aera Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aera Therapeutics Inc. - overview
Established
2021
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in Boston, US, and founded in 2021 by Akin Akinc (CEO), John Maraganore, Robert Nelsen, Issi Rozen, Vicki Sato, David Schenkein, and Josh Wolfe, Aera Therapeutics Inc. is a biotechnology company that uses its proprietary technology to help deliver genetic medicines to various tissues and applications, thereby benefiting more patients across a wider range of disease areas. Aera Therapeutics Inc. is a biotechnology company that uses its proprietary technology to help deliver genetic medicines to various tissues and applications, thereby benefiting more patients across a wider range of disease areas.
In February 2023, Aera Therapeutics Inc. raised Series B funding co-led by new investors ARCH Venture Partners, GV, and Lux Capital. The company uses its proprietary protein nanoparticle (PNP) delivery platform, which leverages the discovery of endogenous, human proteins that can self-assemble into capsid-like structures and package and transfer nucleic acid cargo to enable various genetic medicine modalities. Moreover, the firm also offers a proprietary therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes.
Current Investors
ARCH Venture Partners, GV, Lux Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare
Website
www.aeratx.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Aera Therapeutics Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.